within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AE03_Siponimod;

model Siponimod
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.841,
    Cl = 8.638888888888889e-07,
    adminDuration = 600,
    adminMass = 2.0 / 1000000,
    adminCount = 1,
    Vd = 0.124,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005666666666666667,
    Tlag = 10.020000000000001,
    Vdp = 1.55,
    k12 = 3.1666666666666667e-06,
    k21 = 3.1666666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Siponimod</td></tr><tr><td>ATC code:</td><td>L04AE03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2.0</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>124</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.11</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Siponimod is a selective sphingosine 1-phosphate receptor modulator used primarily for the treatment of relapsing forms of multiple sclerosis (MS), including secondary progressive MS with active disease. It is currently approved and available for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AE03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Siponimod;
